We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Diagnostic Test Kits for Dengue Virus Detection Evaluated

By LabMedica International staff writers
Posted on 28 Oct 2014
Print article
Image: An enzyme-linked immunosorbent assay (ELISA) kit for dengue virus NS1 antigen (Photo courtesy of Diagnostic Automation Inc.).
Image: An enzyme-linked immunosorbent assay (ELISA) kit for dengue virus NS1 antigen (Photo courtesy of Diagnostic Automation Inc.).
Laboratory diagnosis of dengue with a single serum specimen obtained during the acute phase of the illness requires tests to detect immunoglobulin M (IgM) antibodies to Dengue virus or the virus genome.

Commercially available diagnostic test kits for detection of the Dengue virus (DENV) non-structural protein 1 (NS1) and anti-DENV IgM have been evaluated for their sensitivity and specificity and other performance characteristics.

An international team of scientists led by those at the [US] Centers for Disease Control and Prevention (CDC; San Juan, Puerto Rico) examined newly available commercial tests that detect the virus protein NS1, as well as new tests for IgM anti-DENV in microplate or rapid diagnostic test (RDT) formats. This analytic study used specimens from laboratory confirmed dengue patients worldwide, which makes the results widely generalizable.

A DENV NS1 panel cconsisted of a total of 390 dengue patient serum specimens in three sub-panels: 192 dengue patients who were DENV positive by virus isolation and/or polymerase chain reaction (PCR) for DENV ribonucleic acid (RNA), 146 DENV RNA or culture negatives, and 52 challenge specimens from other illnesses or conditions. An anti-DENV IgM panel consisted of three subpanels with 527 patient serum specimens: 228 anti-DENV IgM positive paired specimens from patients with dengue and 155 DENV IgM negative and 144 challenge specimens. All specimens were tested by the solid-phase anti-DENV IgM Antibody Capture Enzyme Linked Immunosorbent Assay (IgM MAC-ELISA).

The DENV kits from seven different manufacturers were tested. The results were analyzed to determine sensitivity, specificity, inter-laboratory and inter-reader agreement, lot-to-lot variation and ease-of-use. NS1 ELISA sensitivity was 60% to 75% and specificity 71% to 80%; NS1 RDT sensitivity was 38% to 71% and specificity 76% to 80%; the IgM anti-DENV RDTs sensitivity was 30% to 96%, with a specificity of 86% to 92%, and IgM anti-DENV ELISA sensitivity was 96% to 98% and specificity 78% to 91%.

The authors concluded that NS1 tests were generally more sensitive in specimens from the acute phase of dengue and in primary DENV infection, whereas IgM anti-DENV tests were less sensitive in secondary DENV infections. The reproducibility of the NS1 RDTs ranged from 92% to 99% and the IgM anti-DENV RDTs from 88% to 94%.The study was published on October 16, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Centers for Disease Control and Prevention 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.